Concepedia

J.W. Goldman

JG

Statistics

Publications

10

Citations

184

H-Index

10

Active since

2015

Affiliations

University of California, Los Angeles(Current)

The University of Texas MD Anderson Cancer Center

Asan Medical Center

Yonsei University

Tel Aviv University

J.W. Goldman is an author at University of California, Los Angeles specializing in oncology, egfr inhibition, and medicine.

Publications per year

2015–2025

10

Publications

10

LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations

Mark A. Socinski, Robin Cornelissen, Marina Chiara Garassino et al. · Annals of Oncology · 2020 · 41 citations

Medicine, Genetics, Oncology +15

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

Masahiro Tsuboi, Yi‐Long Wu, C Grohé et al. · Annals of Oncology · 2022 · 23 citations

Medicine, Oncology, Pharmacology +14

Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy

Deblina Dey, Vipan K. Parihar, Gergely Szabó et al. · Radiation Research · 2020 · 22 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden

Kunal Patel, Richard G. Everson, Jingwen Yao et al. · Neurosurgery · 2020 · 22 citations · Full text

Medicine, Oncology, Radiology +17

1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD

X. Le, L. Hendriks, Alessandro Morabito et al. · Journal of Thoracic Oncology · 2025 · 19 citations · Full text

Medicine, Oncology, Pharmacology +6

1–5 of 10